Cancer Decisions - Free Newsletter -August 5, 2007

HERE AT THE MOSS REPORTS

The sheer volume and complexity of the medical information that the newly diagnosed cancer patient must quickly absorb can be overwhelming. Often, decisions must be made in a hurry, and under great stress. It is not easy under these circumstances to make a careful and fully informed decision.

I have made it my life's work to study the medical literature critically and to question the basis for cancer treatments that have in many instances become universally adopted without ever having been shown to prolong life. I have written and published extensively on the subject of cancer and its treatment, including compiling a comprehensive series of individual reports on more than 200 different cancer diagnoses - The Moss Reports - each one of which examines both the standard treatment options that are likely to be offered for a particular cancer diagnosis, and the possible alternative and complementary approaches to that disease.

If you would like to purchase a Moss Report for yourself or someone you love, you can do so securely from our Web site (www.cancerdecisions.com), or by calling 1-800-980-1234 (814-238-3367 from outside the US).

PHONE CONSULTATIONS

I also offer phone consultations to clients who have bought a Moss Report. A phone consultation can be enormously helpful in drawing up a treatment strategy and getting one's options clearly prioritized. This week, a client offered the following comment:

"Once again, Dr. Moss has provided excellent information and resources in a concise format including names, phone numbers and personal recommendations for therapies to consider that are specific to my diagnosis. He is totally supportive of my approach to use conventional medicine to deal with my current crisis and to use alternative therapies to ensure nothing else goes into crisis mode. He's also been extremely helpful in suggesting alternatives for the future that have excellent prospects for true remission. I can't thank him enough." - R. G.

To schedule an appointment for a phone consultation, please email: Jacquie@cancerdecisions.com, or call 1-800-980-1234 (814-238-3367 from outside the US).

We look forward to helping you.

CURRENT TOPICS

Our Current Topics reports are a series of in depth discussions focusing on subjects of importance in the field of cancer prevention and treatment. These reports, averaging 30 pages in length, can be purchased and downloaded directly from our Web site, www.cancerdecisions.com.

Choose from the following:

On Guard - Gardasil (An in-depth discussion of the anti-cervical cancer vaccine Gardasil)
Do Antioxidants and Chemotherapy Conflict?
Mammography, Biopsy and the Diagnosis of Breast Cancer
Herceptin or Deceptin? (An evaluation of the use of Herceptin in breast cancer)
Avastin: Your Money Or Your Life. (A clear-eyed look at the targeted drug Avastin)
The Politics of Hope: Andrew von Eschenbach and the Decline of the National Cancer Institute
The Mexican Cancer Clinics in the Era of Evidence-Based Medicine

AUDIO NEWSLETTER

To hear the audio version of the newsletter, please click or go to:
http://www.cancerdecisions.com/audio/CD080507.mp3

SUSCRIBE TO OUR PODCAST

To hear the letter podcast on iTunes, please visit:
http://phobos.apple.com/WebObjects/MZStore.woa/wa/viewPodcast?id=215899747

If you do not have iTunes, you may also access our feed at:
http://www.cancerdecisions.com/mossreports.rss

UNMASKING THE TUMOR

There is a common idea that cancer arises simply because of the weakness of the patient's immune system. Supposedly, our white blood cells patrol the highways and byways of the body, looking for cellular miscreants, just as they hunt for viruses and bacteria. According to this popular view, if a patient were to simply enhance his or her immunity, the tumor would disappear. I have known patients who blamed themselves for letting their immune systems get run down, thereby bringing on their own cancers. This view may have an alternative sound to it, but actually is quite orthodox in its origin. It was first propounded in the 1950s by two established scientists, the Nobel laureate Macfarlane Burnet, and the President of Memorial Sloan-Kettering Cancer Center, Dr. Lewis Thomas.

However, this so-called "immune surveillance theory" does not cover many cancers. In fact, cancer strikes many people who are, in most respects, healthy. This was confirmed by a US National Cancer Institute (NCI) study last year. The subjects, in Linzhou, China, were chosen because they were at high risk of developing cancer, particularly of the upper gastrointestinal tract. The immune competence of 381 such individuals was carefully measured via three different lymphocyte stimulation tests. (Lymphocytes are white blood cells responsible for immunity.) Over the next five years, 53 of these participants developed malignant tumors, mostly of the stomach and esophagus. However, NCI scientists could find no significant association between their subjects' immune competence test scores and the subsequent incidence of cancer, or the total death rate. "This implies that immune competence…is not associated with incident cancer or total mortality in this population," they wrote (Roth 2006). There have been several other studies over the years that have reached similar conclusions.

So, if cancer is not generally a result of a simple failure of immune surveillance, then how can we account for the fact that, in the test tube, immune cells are seen to kill cancer cells? The answer to that riddle has also been known for many years. The immune system can have a constructive role to play in fighting cancer. But the problem is that real live cancers actively block an effective immune response from taking place. Tumors produce what are called "blocking factors." This has been repeatedly shown by (among others) Ingegard and Karl Erik Hellstrom, a husband-and-wife team at the University of Washington, who have coauthored hundreds of articles on cancer and the immune system. Starting in the 1960s, the Hellstroms demonstrated that tumors are capable of stopping an effective immune response from taking place. For instance, in 1969 they showed that blood serum from people who had rapidly growing tumors could block the otherwise destructive effects of immune cells (lymphocytes) on various tumor types (Hellstrom 1969).

If it is true that tumors actively block the immune system, what can be done about that? One new possibility, announced a few weeks ago, comes from the laboratory of Douglas D. Taylor, PhD, of the University of Louisville School of Medicine, Louisville, KY. Dr. Taylor has isolated so-called "exosomes," which are blood-borne particles that suppress the immune response in people with solid tumors, as well as leukemias and lymphomas. These exosomes induce the apoptosis (programmed cell death) of T-cells and block T-cell signaling, proliferation and cytokine production. (Cytokines are hormone-like substances produced by the immune system.) Not surprisingly, a high level of exosomes circulating in the blood correlates with both reduced T-cell production and tumor progression.

Through the use of an experimental device called a Hemopurifier®, Taylor was able to remove 60 percent of the exosomes from the blood of ovarian cancer patients in just 10 minutes. He and his colleagues believe this is likely to reverse the immune suppression that is induced by the tumor and to increase the patient's responsiveness to both immunotherapy and chemotherapy, although this still needs to be proven in clinical trials.

The Hemopurifier® was initially developed as a treatment device for victims of biowarfare. The manufacturer claims that the device is able to filter viruses effectively from the blood. But it also clearly has exciting potential in cancer treatment. There have been other attempts along these lines in the past, using devices that were based on modified dialysis machines. But the Hemopurifier® is very compact, about a foot long and an inch wide. (There is also a consumer size that is the size of a large pen!) It needs emphasizing that these devices are still in the testing phase, both for infection and for cancer. But it is exciting to think that some day, small, portable devices may help rid patients of insidious blocking factors that prevent an effective immune response to their cancer.

--Ralph W. Moss, Ph.D.

References:

Business Wire: Aethlon Medical Announces Cancer Treatment Discovery, July 18 2007. Available at:
http://www.genengnews.com/news/bnitem.aspx?name=20459880

Hellstrom IE, et al. Serum-mediated protection of neoplastic cells from inhibition by lymphocytes immune to their tumor specific antigens. Proc Natl Acad Sci U S A. 1969 February; 62(2): 362–368.

Roth MJ, Qiao YL, Abnet CC, et al. Cellular immune response is not associated with incident cancer or total mortality: a prospective follow-up. Eur J Cancer Prev. 2006 Dec;15(6):548-50.

**NOTE** To view this page in a more printable format, please CLICK HERE.

IMPORTANT DISCLAIMER

The news and other items in this newsletter are intended for informational purposes only. Nothing in this newsletter is intended to be a substitute for professional medical advice.